Abstract:Abstract Background On a worldwide basis, the prevalence of hepatocellular carcinoma (HCC) is twice as much in the past two decades, which is the third most common cause in cancer deaths. Therefore there is still an urgent need for new drugs with greater validity against HCC. Autophagy, which is essential in the intracellular clearance of many proteins and organelles, has been closely related to cancer generation and development. Generally, p53 is recognized as a pro-autophagic factor in a transcription-dependent pattern and also an important factor in the progress of HCC. As a selective substrate for autophagy, p62 is a key factor in tumorigenesis on account of its crucial roles in the control of cellular events. Now that small molecule compound-0404 was defined as a DNA-damaging reagent by the p53 pathway, our work aims to examine whether 0404 can affect p53-dependent autophagy and its positive effect in the treatment of HCC. Methods The anti-cancer activity of 0404 was examined in vitro. In the HepG2 cells and Huh7 cells, the apoptosis was detected by Flow Cytometry, while cell viability was measured by the CCK8 Assay. The Hela eGFP-LC3 cells, which express fusion protein combined light chain 3 (LC3) with enhanced Green Fluorescent Protein (eGFP), were treated with 0404 at various concentrations for various time points. HepG2 cells were treated with 0404 at various concentrations (5.0 nM, 20 nM, and 50 nM) for 24h. Autophagy was identified by eGFP-labeled LC3. And the expression levels of autophagy-associated proteins, such as mammalian target of rapamycin (mTOR), phospho-mTOR (p-mTOR), p62 and LC3B, were tested by Western Blotting. Results We confirmed that 0404 could inhibit the proliferation of HepG2 and Huh7 in a dose-dependent manner, and compared to Huh7 cells with mutant p53, HepG2 cells with wild-type p53 were more sensitive to 0404 treatment for apoptosis. We also found that 0404 promoted the development of autophagy in a dose- and time-dependent manner. Compared with untreated group, LC3 in 0404-treated groups resided primarily in the cytoplasm including cytoplasmic puncta indicative of autophagosomes. Simultaneously, the expression levels of mTOR and p62 were down-regulation, while the LC3B expression level was up-regulation by 0404-treatment. And the expression level of p-mTOR was down-regulation in a dose-dependent in HepG2 cells. Conclusion These results show clearly that DNA-damaging reagent-0404 can effectively inhibit HCC through p53-dependent autophagy. Acknowledgment This work was supported by the National Natural Science Foundation of China (81272679) and the Major national S&T Projects (2013ZX09041003). Citation Format: Min Zheng, Bingjue Ye, Guohua Lou, Caixia Xia, Weiyang Zheng, Yanning Yanning, Xiao Xu, Yongchao Zhao, Long Mao, Wanghong Xu. DNA-damaging reagent -0404 effectively inhibits hepatocellular carcinoma through p53-dependent autophagy. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3546.

An autophagy-dependent cell death of MDA-MB-231 cells triggered by a novel Rhein derivative 4F.

A novel Rhein derivative 4F anti-proliferation via paraptosis-like cell death in MCF-7 cells

Discovery of a small molecule targeting ULK1-modulated cell death of triple negative breast cancer in vitro and in vivo

Discovery of Novel Dual-Target Inhibitor of Bromodomain-Containing Protein 4/Casein Kinase 2 Inducing Apoptosis and Autophagy-Associated Cell Death for Triple-Negative Breast Cancer Therapy

Identification and Optimization of 3-Bromo-n'-(4-hydroxybenzylidene)-4-methylbenzohydrazide Derivatives As Mtor Inhibitors That Induce Autophagic Cell Death and Apoptosis in Triple-Negative Breast Cancer.

A Novel 3-Acyl Isoquinolin-1(2H)-one Induces G2 Phase Arrest, Apoptosis and GSDME-dependent Pyroptosis in Breast Cancer

Discovery of a Small-Molecule Bromodomain-Containing Protein 4 (BRD4) Inhibitor That Induces AMP-Activated Protein Kinase-Modulated Autophagy-Associated Cell Death in Breast Cancer.

Discovery of fused benzimidazole-imidazole autophagic flux inhibitors for treatment of triple-negative breast cancer

Systems biology-based discovery of a potential Atg4B agonist (Flubendazole) that induces autophagy in breast cancer

Abstract 3546: DNA-damaging Reagent -0404 Effectively Inhibits Hepatocellular Carcinoma Through P53-Dependent Autophagy

Autophagy blockade sensitizes the anticancer activity of CA-4 via JNK-Bcl-2 pathway.

New Anti-Cancer Strategy to Suppress Colorectal Cancer Growth Through Inhibition of ATG4B and Lysosome Function

Small-molecule RL71-triggered excessive autophagic cell death as a potential therapeutic strategy in triple-negative breast cancer

Coumarin-Furoxan Hybrid Suppressed the Proliferation and Metastasis of Triple-Negative Breast Cancer by Activating Mitochondrial Stress and Cell Apoptosis

ATG 4B Serves a Crucial Role in RCE-4-Induced Inhibition of the Bcl-2–Beclin 1 Complex in Cervical Cancer Ca Ski Cells

A potential strategy for bladder cancer treatment: inhibiting autophagy to enhance antitumor effects of Nectin-4-MMAE

Blocking Autophagy Enhanced Cytotoxicity Induced by Recombinant Human Arginase in Triple-Negative Breast Cancer Cells

Fluoxetine induces autophagic cell death via eEF2K-AMPK-mTOR-ULK complex axis in triple negative breast cancer.

Confirming whether novel rhein derivative 4a induces paraptosis-like cell death by endoplasmic reticulum stress in ovarian cancer cells

A novel protoapigenone analog RY10-4 induces apoptosis of breast cancer cells by regulating mitochondrial Ca2+ influx through the mitochondrial calcium uniporter

YF343, a Novel Histone Deacetylase Inhibitor, Combined with CQ to Inhibit- Autophagy, Contributes to Increased Apoptosis in Triple-Negative Breast Cancer